Revolution Medicines Inc (RVMD) FinancialsRVMDRevolution Medicines Inc

Evaluating the bottom line, Revolution Medicines, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -79.09%, provide a clear picture of how effectively RVMD converts its operational activities into shareholder value.

In the context of the broader market, RVMD competes directly with industry leaders such as ABVX and BHC. With a market capitalization of $43.66B, it holds a leading position in the sector. When comparing efficiency, RVMD's gross margin of N/A stands against ABVX's N/A and BHC's 65.04%. Such benchmarking helps identify whether Revolution Medicines, Inc. is trading at a premium or discount relative to its financial performance.

The company's financial performance shows a concerning trend with net income losses increasing, reaching -644371000 USD in Q2 2026. However, the current ratio remains strong at 11.38, indicating good short-term liquidity.